MedPath

Dextenza for Post-operative Treatment of Pterygium

Phase 4
Conditions
Pterygium of Both Eyes
Interventions
Drug: Intracanalicular Dexamethasone, (0.4 mg) Insert
Registration Number
NCT04351737
Lead Sponsor
Brandon Eye Associates, PA
Brief Summary

DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation Compared to Standard of Care Topical Cortico-steroid Treatment in Patients who Undergo Bilateral Pterygium Surgery

Detailed Description

In patients who undergo bilateral pterygium surgery, eyes will be randomized to receive either DEXTENZA at baseline, Month 1 and Month 2 or prednisolone x 3 months. Both eyes will receive antibiotic drops four times per day for two weeks and Maxitrol ointment at bedtime for two weeks following surgery.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria

patients with bilateral pterygium -

Exclusion Criteria

none

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Pterygium patientsIntracanalicular Dexamethasone, (0.4 mg) Insertpatients with bilateral pterytium
Pterygium patientsPrednisolone Acetatepatients with bilateral pterytium
Primary Outcome Measures
NameTimeMethod
Patient pain level follow pterygium removal2 months

measurement of pain following pterygium removal using the validated "Numeric Pain Rating Scale" to assess pain, which ranges from 0 to 10 with higher values indicating more severe pain.

inflammation2 months

measurement of ocular surface inflammation using the standard 1+ - 4+ rating scale commonly used in ophthalmology with 4+ indicating the most inflammation.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Brandon Eye Associates

🇺🇸

Brandon, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath